Abstract
Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.
Keywords: Cancer epigenetics, DNA methyltransferase inhibitor, Epi-drugs, Epi-miRs, Histone deacetylase inhibitor.
Current Cancer Drug Targets
Title:Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Volume: 16 Issue: 9
Author(s): Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei
Affiliation:
Keywords: Cancer epigenetics, DNA methyltransferase inhibitor, Epi-drugs, Epi-miRs, Histone deacetylase inhibitor.
Abstract: Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.
Export Options
About this article
Cite this article as:
Salarinia Reza, Sahebkar Amirhossein, Peyvandi Mostafa, Mirzaei Reza Hamid, Jaafari Reza Mahmoud, Riahi Matbou Maryam, Ebrahimnejad Hamed, Nahand Sadri Javid, Hadjati Jamshid, Asrami Ostadi Mobina, Fadaei Sara, Salehi Rasoul and Mirzaei Hamed, Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666151207110143
DOI https://dx.doi.org/10.2174/1568009616666151207110143 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Extracellular Citrate in Health and Disease
Current Molecular Medicine Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors
Current Topics in Medicinal Chemistry Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Acute Cystitis Caused by Commensal Neisseria oralis: A Case Report and Review of the Literature
Infectious Disorders - Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued)